Related Experiment Videos
Case study: nefazodone for juvenile mood disorders
T E Wilens1, T J Spencer, J Biederman
1Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, USA.
Summary
Nefazodone shows promise for treating juvenile mood disorders, with 56% of children experiencing significant improvement. This antidepressant was well-tolerated in a small study of treatment-resistant youth.
Area of Science:
- Psychiatry
- Pediatric Medicine
- Pharmacology
Background:
- Juvenile mood disorders are increasingly recognized, yet effective medication options remain limited.
- Nefazodone, a novel antidepressant, has not been previously studied in pediatric populations.
- This study explores nefazodone's efficacy in treatment-refractory children and adolescents with mood disorders.
Observation:
- Seven children and adolescents (mean age 12.4 years) with diagnosed mood disorders were treated with nefazodone.
- Treatment duration averaged 13 weeks, with a mean daily dose of 357 mg.
- Participants had complex conditions, often with multiple prior medication failures and comorbidities.
Findings:
- 56% of participants showed significant improvement in depressive symptoms, as assessed by the Clinical Global Impression scale.
- Two of four children with bipolar depression responded well, while two experienced mild manic activation.
- Nefazodone was generally well-tolerated, with adverse effects reported in only three subjects.
Implications:
- Nefazodone may represent a viable treatment option for pediatric mood disorders, particularly in cases resistant to other therapies.
- The observed tolerability suggests a favorable safety profile in this population.
- Further rigorous, controlled clinical trials are necessary to confirm these preliminary findings and establish definitive treatment guidelines.